Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PSG1/CD66f drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PSG1/CD66f ECD-Fc Recombinant Protein High purity (>95%), Endotoxin <1.0 EU/μg. HEK293 expressed for native glycosylation. Sequence Verified. |
View PSG1 Products |
| Gene Delivery | PSG1/CD66f Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression validation. |
View PSG1 Products |
| Benchmark Ab | Anti-PSG1/CD66f Recombinant Antibody Recombinant positive control antibody for assay calibration. Sequence verified. |
View PSG1 Products |
| Validator | PSG1/CD66f siRNA Set Target-specific knockdown verification in functional assays. |
View PSG1 Products |
| Related Target A | CEACAM1 Closely related CEA family member. Critical for subfamily off-target and cross-reactivity screening. |
View CEACAM1 Products |
| Related Target B | TGFB1 Downstream effector pathway. PSG1 binds and activates latent TGF-beta1 to drive immunomodulation. |
View TGFB1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| CEACAM Subfamily Cross-Reactivity | Highly purified CEACAM1/3/5/6 panel proteins available with >95% purity for counter-screening. |
| Glycosylation-Dependent Epitope Mapping | HEK293 mammalian expression host preserves native, complex post-translational modifications. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live PSG1/CD66f R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of Pregnancy-Specific Beta-1-Glycoprotein 1 (PSG1/CD66f) is an emerging frontier in immune-oncology and reproductive medicine. Traditionally known as a pregnancy marker, PSG1 is increasingly recognized as an immune-modulatory factor overexpressed in various solid tumors (such as choriocarcinoma, breast cancer, and colorectal cancer) where it facilitates immune evasion. The race for PSG1 therapeutics is intensifying, with major players shifting focus from traditional mAbs to multi-specific antibody formats and targeted delivery systems. As first-generation therapies reach the clinic, the next wave of R&D is targeting the precise disruption of the PSG1-TGF-beta signaling axis to restore anti-tumor immunity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (mAbs) | Biotech Innovators, Academic Research Consortia | Solid Tumors, Choriocarcinoma | Blockade Assay (Need high-purity HEK293-expressed ECD-Fc) |
| Bispecific / Multi-specifics | Oncology-focused Biopharma | Immune-evasive Cancers | Simultaneous binding validation (Need cross-reactive antigens) |
| Diagnostic / Prognostic Tools | In Vitro Diagnostic (IVD) Companies | Preeclampsia, Pregnancy Monitoring | High-affinity capture reagents (Need sequence-verified antigens) |